New miREIA kits from BioVendor
Open doors to microRNA biomarker world

miREIA is a novel immunoassay-based method for miRNA quantification. The assay can be performed using standard ELISA equipment.

hsa-miR-142-5p miREIA (Cat. No: RDM0001H)
hsa-miR-142-5p is upregulated in leprosy and several other diseases related to the immune response. Abnormal expression of this miRNA has been elaborated in various tumors. The expression of hsa-miR-142-5p was greatly overexpressed in cutaneous squamous cell carcinoma (cSCC). It was also confirmed that inhibition of this miRNA repressed cSCC cell growth and induced apoptosis, while upregulation exhibited a reverse phenomenon. miR-142-5p can trigger cancer stem cell-like properties of cSCC. Increased level of miR-142-5p was observed in the serum of colorectal cancer patients compared to healthy controls. Elevated expression of this miRNA was revealed also in renal cell carcinoma tissues and cell lines. Dysregulated expression of miR-142-5p contributes to the pathogenesis of Alzheimer disease by triggering synaptic dysfunction associated with amyloid beta-mediated pathophysiology.

hsa-miR-93-5p miREIA (Cat. No: RDM0002H)
hsa-miR-93-5p is an onco-miRNA. Up-regulation of miR-93-5p is correlated with worse clinic-pathological features and can serve as an independent marker for poor prognosis in patients with non-small cell lung cancer. NSCLC cell proliferation, migration, and invasion were significantly stimulated by miR-93-5p upregulation and inhibited by miR-93-5p downregulation. miR-93-5p was also up-regulated in non-muscle invasive bladder cancer. Increased expression of circulating miR-93-5p in women with polycystic ovary syndrome may represent a novel non-invasive biomarker for diagnosis.

hsa-miR-21-5p miREIA (Cat. No: RDM0001H)
hsa-miR-21-5p is a circulating miRNA, strongly conserved through evolution, which has been extensively investigated in a range of studies of various diseases, such as cancer, cardiovascular disease, pulmonary diseases, regulation of immunological processes, and many others. hsa-miR-21-5p is typical onco-miRNA. Up-regulated hsa-miR-21-5p could promote tumor growth, metastasis and invasion and reduce sensitivity to chemotherapy. Besides altered expression in various malignancies, this miRNA is highly expressed also in the cardiovascular system. hsa-miR-21-5p has been found to play important roles in vascular smooth muscle cell proliferation and apoptosis, cardiac cell growth and death, calcific aortic valve disease and cardiac fibroblast functions.

hsa-miR-150-5p miREIA (Cat. No: RDM0004H)
hsa-miR-150-5p is linked with number of cancers. It was up-regulated in plasma of melanoma patients. Findings also demonstrate miR-150-5p as a putative novel biomarker of inflammatory active disease with the potential to be used for early diagnosis of multiple sclerosis, miR-150-5p is downregulated in children with tuberculosis. In aplastic anemia, levels of miR-150-5p were elevated, compared to healthy controls. miR-150-5p is expressed in the lymph nodes, spleen and thymus and it is highly up-regulated during lymphocyte maturation and down-regulated during the activation of mature B and T cells. In vivo studies show that miR-150 is released in the external environment after T cell activation and this may cause an increase of its blood levels during immune system stimulation.

hsa-miR-191-5p miREIA (Cat. No: RDM0005H)
hsa-miR-191-5p is dysregulated in many types of cancers (>20) and various other diseases like T2DM, pulmonary hypertension, Crohn's and Alzheimer's diseases. miR-191-5p regulates important cellular processes such as cell proliferation, differentiation and apoptosis. miR-191-5p is a promising disease biomarker and therapeutic target.

hsa-miR-24-3p miREIA (Cat. No: RDM0012H)
hsa-miR-24-3p is linked with number of malignances. miR-24-3p is over-expressed in hepatocellular carcinoma, nasopharyngeal carcinoma, contribute to ovarian cancer cell chemoresistance, regulates bladder cancer cell proliferation, accelerate the migration and invasion and inhibit the apoptosis. In colorectal adenocarcinoma, elevated expression is a potentially adverse prognostic factor, where high expression predicts poor disease-free survival and overall survival. Uppregulated expression of miR-24-3p was observed in peripheral blood mononuclear cells of patients with chronic obstructive pulmonary disease. The expression of miR-24-3p was upregulated in peripheral blood mononuclear cells (PBMCs) of patients with chronic obstructive pulmonary disease (COPD) compared with smokers without airflow limitation. The plasma levels of hsa-miR-24-3p are downregulated in patients with hypercholesterolemia compared to controls.
Available miREIA kits

- cel-miR-39-3p miREIA (Cat. No: RDM0000C)
- hsa-miR-1-3p miREIA (Cat. No: RDM0019H)
- hsa-miR-let-7a-5p miREIA (Cat. No: RDM0023H)
- hsa-miR-let-7b-5p miREIA (Cat. No: RDM0027H)
- hsa-miR-15a-5p miREIA (Cat. No: RDM0007H)
- hsa-miR-16-5p miREIA (Cat. No: RDM0008H)
- hsa-miR-21-5p miREIA (Cat. No: RDM0001H)
- hsa-miR-23a-3p miREIA (Cat. No: RDM0009H)
- hsa-miR-24-3p miREIA (Cat. No: RDM0012H)
- hsa-miR-26b-5p miREIA (Cat. No: RDM0028H)
- hsa-miR-29a-3p miREIA (Cat. No: RDM0034H)
- hsa-miR-92a-3p miREIA (Cat. No: RDM0020H)
- hsa-miR-93-5p miREIA (Cat. No: RDM0002H)
- hsa-miR-100-5p miREIA (Cat. No: RDM0039H)
- hsa-miR-126-3p miREIA (Cat. No: RDM0018H)
- hsa-miR-129-5p miREIA (Cat. No: RDM0031H)
- hsa-miR-136-5p miREIA (Cat. No: RDM0025H)
- hsa-miR-137-3p miREIA (Cat. No: RDM0037H)
- hsa-miR-142-5p miREIA (Cat. No: RDM0013H)
- hsa-miR-145-5p miREIA (Cat. No: RDM0003H)
- hsa-miR-146a-5p miREIA (Cat. No: RDM0024H)
- hsa-miR-150-5p miREIA (Cat. No: RDM0004H)
- hsa-miR-155-5p miREIA (Cat. No: RDM0017H)
- hsa-miR-191-5p miREIA (Cat. No: RDM0005H)
- hsa-miR-192-5p miREIA (Cat. No: RDM0035H)
- hsa-miR-197-3p miREIA (Cat. No: RDM0010H)
- hsa-miR-203a-3p miREIA (Cat. No: RDM0040H)
- hsa-miR-210-3p miREIA (Cat. No: RDM0029H)
- hsa-miR-222-3p miREIA (Cat. No: RDM0014H)
- hsa-miR-223-3p miREIA (Cat. No: RDM0015H)
- hsa-miR-324-5p miREIA (Cat. No: RDM0032H)
- hsa-miR-361-5p miREIA (Cat. No: RDM0030H)
- hsa-miR-423-3p miREIA (Cat. No: RDM0021H)
- hsa-miR-423-5p miREIA (Cat. No: RDM0033H)
- hsa-miR-451a miREIA (Cat. No: RDM0006H)
- hsa-miR-486-5p miREIA (Cat. No: RDM0022H)
- hsa-miR-625-5p miREIA (Cat. No: RDM0041H)
- hsa-miR-5100 miREIA (Cat. No: RDM0042H)
- hsa-piR-5937 miREIA (Cat. No: RDM0038H)
- mmu-miR-7052-5p miREIA (Cat. No: RDM0026M)

Contact Information

BioVendor – Laboratorni medicina a.s.
Karaske 1767/1, 621 00 Brno, Czech Republic
Phone: +420 549 124 185, Fax: +420 549 211 460
E-mail: info@biovendor.com

BioVendor GmbH
Otto-Hahn-Straße 16, 34123 Kassel, Germany
Phone: +49 (0)561 861 509 33, Fax: +49 (0)561 861 509 34
E-mail: infoEU@biovendor.com

BioVendor LLC
128 Bingham Rd., Suite 1300, Asheville, NC 28806, USA
Phone: +1-800-404-7807, Phone: +1-828-575-9250
Fax: +1-828-575-9251, E-mail: infoUSA@biovendor.com

Oxford Biosystems Ltd
184B Park House, Park Drive
Milton Park, Abingdon, Oxfordshire
OX14 4SR, United Kingdom
Phone: +44 (0)1235 431390
E-mail: sales@oxfordbiosystems.com

For more information please visit www.biovendor.com/mirna